Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) Income from Continuing Operations (2016 - 2025)

Dare Bioscience's Income from Continuing Operations history spans 8 years, with the latest figure at 1471268.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 72.69% year-over-year to 1471268.0; the TTM value through Dec 2025 reached 13529763.0, up 42.6%, while the annual FY2025 figure was 13552334.0, 42.21% up from the prior year.
  • Income from Continuing Operations reached 1471268.0 in Q4 2025 per DARE's latest filing, up from 3672148.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 384322.0 in Q2 2022 to a low of 16230567.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 6924806.6, with a median of 7249129.5 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: soared 104.19% in 2022, then crashed 2439.02% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 9543115.0 in 2021, then plummeted by 70.08% to 16230567.0 in 2022, then surged by 68.14% to 5171460.0 in 2023, then decreased by 4.19% to 5388197.0 in 2024, then soared by 72.69% to 1471268.0 in 2025.
  • Per Business Quant, the three most recent readings for DARE's Income from Continuing Operations are 1471268.0 (Q4 2025), 3672148.0 (Q3 2025), and 3827800.0 (Q2 2025).